Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer-Reference-Cited by-同舟云学术

Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer

Published:2017-10 Issue:10 Volume:43 Page:1855-1861
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology (EJSO)
language:en
Short-container-title:European Journal of Surgical Oncology (EJSO)

Author:

Liao G.-S.^ORCID,Dai M.-S.,Hsu H.-M.,Chu C.-H.,Hong Z.-J.,Fu C.-Y.,Chou Y.-C.,Huang T.-C.,Yu J.-C.

Funder

Tri-Service General Hospital's project

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference25 articles.

1. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011;Goldhirsch;Ann Oncol – Off J Eur Soc Med Oncol/ESMO,2011

2. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer;Li;Cancer Res,2009

3. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy;Wong;Ann Acad Med Singapore,2011

4. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol – Off J Eur Soc Med Oncol/ESMO,2009

5. Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients;Schwentner;BMC Cancer,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status;Clinical Epigenetics;2021-10-03

2. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR;PLOS ONE;2021-09-23

3. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?;The Breast Journal;2020-10

4. Long-term prognostic effect of hormone receptor subtype on breast cancer;Breast Cancer Research and Treatment;2019-10-08

5. Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer;European Journal of Surgical Oncology;2018-04